China SXT Pharmaceuticals, Inc. (SXTC) Income Statement
SXTC FY2026 at a glance
Fiscal year ended March 31, 2026 · U.S. dollarsSXTC revenue and net income
Where SXTC's revenue goes
FY2026Each bar shows an amount and its share of revenue. SXTC kept −578.5% of revenue as net income.
SXTC profit margins
SXTC growth rates
to FY2026| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −38.4% | −18.4% | −25.8% | −11.7% |
| Gross profit | −50.1% | −24.5% | −42.2% | −13.6% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
SXTC quarterly EPS vs estimates
China SXT Pharmaceuticals beat the analyst EPS estimate in 0 of the last 4 quarters.
SXTC income statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $1.7M | $1.9M | $2.0M | $2.6M | $4.8M | $5.2M | $7.0M | $7.0M | $4.9M |
| Cost of revenue | $889,350 | $1.4M | $1.4M | $1.5M | $1.4M | $1.9M | $2.5M | $2.4M | $3.6M | $2.6M |
| Gross profit | $183,282 | $367,427 | $553,971 | $426,271 | $1.3M | $2.8M | $2.7M | $4.6M | $3.4M | $2.3M |
| Research & development | $178,765 | $191,393 | $184,194 | — | — | — | — | — | — | — |
| Sales, general & admin | $7.1M | $2.8M | $2.6M | $6.0M | $6.4M | $5.0M | $4.0M | $2.8M | $1.8M | $709,819 |
| Total operating expenses | $7.3M | $3.0M | $3.1M | $6.0M | $6.4M | $5.0M | $4.0M | $2.8M | $1.8M | $709,819 |
| Operating income | −$7.1M | −$2.7M | −$2.5M | −$5.6M | −$5.2M | −$2.2M | −$1.3M | $1.8M | $1.6M | $1.6M |
| Interest income | — | — | — | — | — | — | — | $5,170 | $780 | $40,390 |
| Interest expense | $62,965 | $648,221 | $544,279 | $476,776 | $36,695 | $1.6M | $3.3M | $5,174 | $779 | $40,390 |
| Income before taxes | −$6.1M | −$3.3M | −$3.1M | −$5.9M | −$5.4M | −$2.9M | −$10.4M | $1.8M | $1.6M | $1.6M |
| Income taxes | $130,840 | — | $3 | $476,776 | $328,146 | −$192,683 | −$101,722 | $252,232 | $440,103 | $395,049 |
| Net income | −$6.2M | −$3.3M | −$3.1M | −$5.9M | −$5.7M | −$2.7M | −$10.3M | $1.5M | $1.2M | $1.2M |
| EBITDA | −$7.0M | −$2.6M | −$2.4M | −$5.2M | −$5.1M | −$1.9M | −$1.0M | $2.0M | $1.8M | $1.7M |
| EPS (diluted) | −$10.59 | −$5.64 | −$1.27 | −$6.84 | −$13.29 | −$52.75 | −$1.22 | −$0.05 | $0.15 | $0.15 |
| Gross margin | 17.1% | 21.1% | 28.7% | 21.6% | 48.1% | 59.4% | 52.4% | 65.8% | 48.5% | 47.4% |
| Operating margin | −664.1% | −154.0% | −130.4% | −284.4% | −199.4% | −46.0% | −26.0% | 25.2% | 23.3% | 32.8% |
| Net margin | −578.5% | −189.8% | −160.7% | −301.0% | −220.4% | −57.5% | −199.3% | 22.0% | 16.9% | 24.3% |
| Jun '26 | Dec '25 | Sep '25 | Jun '25 | Dec '24 | Jun '24 | Dec '23 | Sep '23 | Jun '23 | Dec '22 | Sep '22 | Jun '22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2M | $255,741 | $626,570 | $0 | $455,709 | $414,745 | $751,073 | $898,163 | $469,791 | $381,696 | $1.2M | $0 |
| Cost of revenue | $364,502 | $182,251 | $524,848 | −$182,251 | $339,372 | $347,368 | $361,642 | $753,992 | $325,621 | $213,402 | $1.1M | $4.0M |
| Gross profit | $833,974 | $73,490 | $101,722 | −$825,904 | $116,337 | $67,377 | $389,431 | $144,171 | $144,170 | $168,294 | $89,684 | −$15.5M |
| Sales, general & admin | $1.4M | $465,495 | $6.4M | $3.2M | $1.1M | $386,511 | $3.6M | $4.8M | $4.8M | $2.2M | $620,065 | $3.1M |
| Total operating expenses | $1.6M | $465,494 | $6.4M | −$1.2M | $1.1M | $386,511 | −$3.0M | $4.8M | $4.8M | $2.4M | $1.2M | $8.4M |
| Operating income | −$784,008 | −$392,004 | −$6.3M | −$3.2M | −$1.0M | −$319,134 | $3.4M | −$4.7M | −$4.7M | −$2.2M | −$1.2M | $1.3M |
| Interest expense | $31,640 | $15,820 | $31,325 | $15,820 | $232,875 | $91,236 | $103,880 | $336,520 | $92,490 | — | $384,286 | $3.6M |
| Income before taxes | −$1.2M | $81,858 | −$6.4M | $1.4M | −$1.3M | −$401,284 | $2.8M | −$90,728 | −$4.8M | −$2.2M | −$747,300 | $2.4M |
| Income taxes | −$1.4M | — | — | — | — | −$10.9M | −$513,232 | $4.8M | $5,310 | — | $4 | −$596,164 |
| Net income | $163,718 | $81,858 | −$6.4M | −$81,858 | −$1.3M | −$401,284 | $3.3M | −$4.8M | −$4.8M | −$2.2M | −$1.5M | $2.3M |
| EBITDA | −$672,889 | −$336,445 | −$6.3M | $336,445 | −$1.0M | −$240,638 | $3.7M | −$4.6M | −$4.6M | −$2.0M | −$465,257 | $5.0M |
| EPS (diluted) | — | — | −$0.05 | −$1.02 | −$1.99 | — | — | — | — | — | — | −$2.03 |
| Gross margin | 69.6% | 28.7% | 16.2% | — | 25.5% | 16.2% | 51.8% | 16.1% | 30.7% | 44.1% | 7.4% | — |
| Operating margin | −65.4% | −153.3% | −1,011.7% | — | −224.1% | −76.9% | 454.9% | −520.5% | −995.0% | −583.8% | −95.2% | — |
| Net margin | 13.7% | 32.0% | −1,016.5% | — | −274.4% | −96.8% | 439.2% | −539.8% | −1,032.0% | −581.6% | −123.7% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in SXTC's financial statements (latest annual report filed July 1, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
SXTC financial results
In fiscal year 2026 (ended March 31, 2026), China SXT Pharmaceuticals reported revenue of $1.1 million, down 38.4% from the year before. It had a net loss of $6.2 million, a net profit margin of −578.5%. Diluted earnings per share came to −$10.59. Over five years revenue grew at an average rate of −25.8% a year.
See the SXTC stock overview for the latest quote and news, or the SXTC chart for price history and technical indicators.
SXTC income statement FAQ
What is China SXT Pharmaceuticals's annual revenue?
China SXT Pharmaceuticals reported total revenue of $1.1 million for fiscal year 2026, which ended on March 31, 2026. That was down 38.4% from $1.7 million the previous year.
Is China SXT Pharmaceuticals profitable?
No. China SXT Pharmaceuticals reported a net loss of $6.2 million in fiscal 2026, a net profit margin of −578.5%; its operating margin was −664.1%.
What is China SXT Pharmaceuticals's gross margin?
China SXT Pharmaceuticals's gross margin was 17.1% in fiscal 2026: for every $100 of revenue, China SXT Pharmaceuticals kept $17 after the direct cost of its products and services.
How much does China SXT Pharmaceuticals spend on research and development?
China SXT Pharmaceuticals spent $0.2 million on research and development in fiscal 2026, 16.7% of revenue.
How fast is China SXT Pharmaceuticals growing?
Revenue grew −25.8% a year on average over the last five fiscal years, from $4.8 million to $1.1 million.
What are China SXT Pharmaceuticals's earnings per share?
China SXT Pharmaceuticals earned $-10.59 per diluted share in fiscal 2026, compared with $-5.64 a year earlier.
When does China SXT Pharmaceuticals's fiscal year end?
China SXT Pharmaceuticals's fiscal year ends in March. The latest annual report covers the year ended March 31, 2026 and was filed on July 1, 2026.